QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

NBTX

QT72Nanobiotix S.A.
NASDAQ·Healthcare·Biotechnology·FR
Latest market price
36.27
+0.20+0.55%
OverviewShort InterestFilings
NBTXQT72Nanobiotix S.A.·NASDAQ
OverviewShort InterestFilings
36.27+0.55%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-2.12
Insider Own-
Shs Outstand50.62M
Perf Week2.66%
Market Cap1.80BForward P/E-EPS next Y-0.09Insider Trans-Shs Float-Perf Month-21.49%
Enterprise Value1.85BPEG-EPS next Q-0.36Inst Own-Short Float-Perf Quarter14.74%
Income-29510612.00P/S52.94EPS this Y89.33%Inst Trans-Short Ratio-Perf Half Y62.50%
Sales33.99MP/B-EPS next Y58.66%ROA-35.36%Short Interest-Perf YTD56.88%
Book/sh-1.96P/C-EPS next 5Y-ROE31.23%52W High57.14 -36.52%Perf Year688.48%
Cash/sh1.22P/FCF-EPS past 3/5Y-ROIC-74.29%52W Low4.18 767.70%Perf 3Y-
Dividend Est.-EV/EBITDA-133.56Sales past 3/5Y87.58% 61.54%Gross Margin100.00%Volatility6.58% 5.69%Perf 5Y-
Dividend TTM-EV/Sales54.38EPS Y/Y TTM-35.07%Oper. Margin-36.49%ATR (14)2.99Perf 10Y-
Dividend Ex-Date-Quick Ratio1.09Sales Y/Y TTM412.50%Profit Margin-80.83%RSI (14)46.00Recom2.25
Dividend Gr. 3/5Y-Current Ratio1.09EPS Q/Q-39.38%SMA20-2.72%Beta2.29Target Price38.00
Payout0.00%Debt/Eq-1.13Sales Q/Q-91.43%SMA50-4.36%Rel Volume0.64Prev Close36.07
Employees108LT Debt/Eq-1.08EarningsSep 30SMA20036.90%Avg Volume77.92KPrice36.27
IPO DateDec 11, 2020Option/ShortYes / YesEPS/Sales Surpr.-250.74% -92.31%Net Debt/EBITDA-3.53Volume49,583Change0.55%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-04-26ReiteratedLeerink PartnersOutperform$26 → $46
May-01-26ReiteratedUBSNeutral$30
Nov-25-25ReiteratedLeerink Partners$14 → $26
Sep-18-25ReiteratedLeerink Partners$9.00 → $14
Aug-27-24InitiatedGuggenheimBuy$12
Latest News
Jun-12-26
Jun-12-2604:58PM
Nanobiotix: A Royalty-Backed Physics Platform Hidden Inside A BiotechSeekingAlpha
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue2533-8
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A
000
Gross Profit2533-8
Selling, General and Administrative Excl. Other452322
Research and Development702644
Other Operating Expense-4-30
Operating Income-86-12-74
Interest Expense12129
Unusual Expense
———
Non-Operating Income (Expense)330
Net Income Before Taxes-100-27-74
Income Taxes
000
Consolidated Net Income-101-27-74
Net Income From Continuing Operations-101-27-74
Net Income-101-27-74
EPS (Recurring)-2.12-0.56-1.56
EPS (Basic, Before Extraordinaries)-2.12-0.56-1.56
EPS (Diluted)-2.12-0.56-1.56
EBITDA-85-14-73
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio69.6433.63—
Gross Margin100.00100.00100.00
Operating Margin-344.00-36.36925.00
Net Margin-404.00-81.82925.00
Shares Outstanding484847
Market Capitalization1,7411,110—
Operating Lease Expense
———
Insider Trading Volume
$40.52$35.73$30.95$26.17$21.38● Close Price0.00K0.00K0.00K0.00K0.00KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR